Decoy Therapeutics' CEO is Rick Pierce, appointed in Nov 2025, has a tenure of less than a year. total yearly compensation is $412.95K, comprised of 7.2% salary and 92.8% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth $12.39K. The average tenure of the management team and the board of directors is 0.6 years and 6.9 years respectively.
Key information
Rick Pierce
Chief executive officer
US$413.0k
Total compensation
CEO salary percentage
7.17%
CEO tenure
less than a year
CEO ownership
0.3%
Management average tenure
less than a year
Board average tenure
6.9yrs
Recent management updates
Recent updates
CEO Compensation Analysis
How has Rick Pierce's remuneration changed compared to Decoy Therapeutics's earnings?
Date
Total Compensation
Salary
Company Earnings
Mar 31 2026
n/a
n/a
-US$13m
Dec 31 2025
US$413k
US$30k
-US$13m
Compensation vs Market: Rick's total compensation ($USD412.95K) is below average for companies of similar size in the US market ($USD632.19K).
Compensation vs Earnings: Insufficient data to compare Rick's compensation with company performance.
CEO
Rick Pierce (64 yo)
less than a year
Tenure
US$412,952
Compensation
Mr. Frederick E. Pierce, II, also known as Rick, is CEO & Director of Salarius Pharmaceuticals, Inc. from November 12, 2025. Mr. Pierce Mr. Pierce serves as Chief Executive Officer at Decoy Therapeutics In...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Frederick Pierce
CEO & Director
less than a year
US$412.95k
0.26% $ 12.4k
Mark Rosenblum
Executive VP of Finance & CFO
6.8yrs
US$569.00k
0.32% $ 15.0k
Barbara Hibner
Chief Scientific Officer
less than a year
US$417.48k
no data
Peter Marschel
Chief Business Officer
less than a year
US$417.53k
no data
Nadeem Mirza
Senior Vice President of Clinical Development
5.9yrs
no data
no data
0.6yrs
Average Tenure
64yo
Average Age
Experienced Management: DCOY's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Board Members
Name
Position
Tenure
Compensation
Ownership
Frederick Pierce
CEO & Director
less than a year
US$412.95k
0.26% $ 12.4k
Jonathan Lieber
Independent Director
6yrs
US$33.50k
0.00038% $ 18.0
Paul Lammers
Independent Director
6.9yrs
US$30.00k
0.00019% $ 9.0
Arnold Hanish
Independent Director
6.9yrs
US$40.00k
0.078% $ 3.7k
William McVicar
Independent Chairman of the Board
6.9yrs
US$50.00k
0.00038% $ 18.0
Teresa Burleson
Independent Director
6.9yrs
US$33.50k
0.00038% $ 18.0
David Arthur
Director
6.9yrs
US$106.23k
0.0064% $ 303.2
6.9yrs
Average Tenure
64yo
Average Age
Experienced Board: DCOY's board of directors are considered experienced (6.9 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/01 13:45
End of Day Share Price
2026/05/29 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Decoy Therapeutics Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.